- Policy
- Reimbursement of new migraine drugs gain momentum
- by Lee, Tak-Sun Jul 11, 2022 06:04am
- New migraine drugs are competitively pushing to receive reimbursement listing in Korea. Following Lilly’s ‘Emgality (galcanezumab)’ in May, Ildong Pharmamceutical’s ‘'Reyvow (lasmiditan)’ has also passed deliberations by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee (DREC) on the
- Policy
- ↑Rosuvastatin when combined with Brilinta/Rosuvastatin
- by Lee, Hye-Kyung Jul 11, 2022 06:04am
- According to a recent review of EMA safety information, the MFDS decided to establish a new clause on the interaction that combination of Ticagrelor and Rosuvastatin can affect kidney excretion and increase the risk of Rosuvastatin accumulation. According to the new clause, the exact mechanism of action for side effects was not known, but com
- Policy
- New Donepezil & a dilemma over low drug prices
- by Lee, Tak-Sun Jul 11, 2022 06:03am
- Domestic pharmaceutical companies are releasing a new form of Donepezil, a component of dementia treatment, but existing low-cost drugs are acting as a dilemma. Donepezil accounts for about 80% of dementia treatments, so competition among the same products is fierce. As there are 150 pharmaceutical companies with the same ingredient products,
- Policy
- Hemophilia Type A tx, Bayer's Jivi has been approved
- by Lee, Hye-Kyung Jul 10, 2022 03:35pm
- Bayer's hemophilia type A treatment Jivi has been approved for domestic items. The MFDS recently granted Jivi to routine prophylaxis for on-demand and suppression of bleeding episodes in adults and adolescents (blood coagulation factor VIII birth deficiency) who have been treated before, management of bleeding before and after surgery, and r
- Policy
- The MFDS announced the designation of 4 temporary narcotics
- by Lee, Hye-Kyung Jul 7, 2022 05:54am
- The MFDS (Director Oh Yoo-kyung) announced on the 5th that it will designate four types, including 1V-LSD, which are used as substitute substances for drugs. 1V-LSD is newly designated as Class I temporary drug, and CH-PIATA is newly designated as Class II temporary drug. 1V-LSD has a structure similar to that of LSD and is a material whic
- Policy
- Antiepileptic perampanel’s adverse event rate at 32%
- by Lee, Hye-Kyung Jul 5, 2022 05:59am
- Results of the 6-year post-marketing surveillance (PMS) on the antiepileptic ingredient perampanel showed that 17 cases of serious adverse reactions whose causal relationship cannot be ruled out were reported. As 287 cases of unexpected adverse reactions whose causal relationship cannot be ruled out were also reported, the indication for
- Policy
- The revaluation of Streptokinase could be maintained for 1yr
- by Lee, Tak-Sun Jul 5, 2022 05:59am
- The pharmaceutical industry expects some components to be suspended in this year's benefit revaluation. The benefit revaluation of Streptokinase and Streptodornase, which are scheduled to submit a report on clinical revaluation results next year, could be suspended for one year. However, the final plan is expected to be decided through delibe
- Policy
- Support for online conferences will be extended for 1 yr
- by Kim, Jung-Ju Jul 5, 2022 05:58am
- On-off events can be supported on an offline basis if certain conditions are met Temporary support for online academic conferences in medical, pharmaceutical, and medical devices will be extended for another year. This is because infectious diseases such as COVID-19 and monkeypox continue to occur, leaving room for reinforcement of social dis
- Policy
- Korea joined the COVID-19 vaccine development country
- by Lee, Hye-Kyung Jul 4, 2022 05:54am
- As SK Bioscience's COVID-19 vaccine SKY Covione received an item permit today (29th), Korea has become a country with both COVID-19 treatments and vaccines along with Celltrion's COVID-19 treatment Regkirona. Oh Yu-kyung, Minister of Food and Drug Safety announced on June 29 that it decided to grant item permission on condition that SKY Covi
- Policy
- Evusheld granted emergency use for preventing COVID-19
- by Lee, Hye-Kyung Jul 1, 2022 05:50am
- With the emergency use authorization has been granted for ‘Evusheld Inj,’ the first-ever preventive antibody therapy for COVID-19 in Korea, the drug is expected to be used in immunocompromised patients who are unlikely to mount an adequate response to COVID-19 vaccinations. The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) a
